AbbVie, schizophrenia

AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.
AbbVie's closely watched schizophrenia drug fails two studies, shares slide
AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5% in early trading.
AbbVie Stock Falls on Schizophrenia Drug Study Failure
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks,
AbbVie Says Phase 2 Trials Of Emraclidine In Schizophrenia Did Not Meet Primary Endpoint
Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that its two Phase 2 EMPOWER trials investigating emraclidine as a
AbbVie's schizophrenia drug misses main goals of two trials
(Reuters) -AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading. The drug, emraclidine,
AbbVie declines after missing main goal in schizophrenia treatment trials
AbbVie (NYSE:ABBV) shares dropped about 11% after its late-stage trials investigating emraclidine as an oral monotherapy treatment for adults with schizophrenia experiencing acute exacerbation of psychotic symptoms,
BioSpace17h
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Stocktwits on MSN2h
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays Stoic
Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...
The Financial Times2h
AbbVie shares tumble after schizophrenia drug disappoints
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AbbVie shares tumbled more than 10 per cent on Monday, wiping more than $30bn from the drugmaker’s market ...
pharmaphorum1h
Advantage BMS as AbbVie drug fails schizophrenia trials
Shares in AbbVie have slumped after a pair of failed phase 2 trials ... Discover how AI is transforming the pharma ...
STAT17h
Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more
The pharmaceutical industry is poised for an opportunity to tweak parts of the Medicare drug pricing negotiation law, after ...
AbbVie banks on Alzheimer's therapy with $1.4 billion buy of Aliada
U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
AbbVie: 3 Positives From The Earnings Report
With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...
MM&M13d
AbbVie takes bet on new Alzheimer’s drug in $1.4 billion acquisition of Aliada Therapeutics
The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.
GlobalData on MSN10d
AbbVie and EvolveImmune Therapeutics sign oncology collaboration
AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...